ImmunoMod is a privately held biopharmaceutical company developing and commercializing innovative therapies for the prevention and cure of diabetes and related metabolic disorders. Our platform utilizes immune-modulating molecules as prophylactics, by leveraging their ability to attenuate inflammatory destruction. Developing an effective therapeutic to protect beta cell function in early onset Type I diabetics is our first priority and the efficacy of our lead drug candidate IM-ASN to preserve these cells has been evidenced in animal and compassionate human studies.

